$1.55 Million in Sales Expected for AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) This Quarter

Share on StockTwits

Analysts expect that AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) will announce $1.55 million in sales for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for AcelRx Pharmaceuticals’ earnings. The highest sales estimate is $3.50 million and the lowest is $730,000.00. AcelRx Pharmaceuticals posted sales of $820,000.00 in the same quarter last year, which suggests a positive year over year growth rate of 89%. The company is expected to issue its next earnings results on Thursday, August 1st.

According to Zacks, analysts expect that AcelRx Pharmaceuticals will report full-year sales of $8.57 million for the current fiscal year, with estimates ranging from $6.41 million to $11.90 million. For the next fiscal year, analysts expect that the company will report sales of $35.43 million, with estimates ranging from $29.00 million to $47.20 million. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for AcelRx Pharmaceuticals.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last issued its quarterly earnings data on Wednesday, May 8th. The specialty pharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.06. The company had revenue of $0.27 million during the quarter, compared to analysts’ expectations of $0.85 million.

ACRX has been the topic of several research analyst reports. BidaskClub upgraded shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, April 1st. Zacks Investment Research upgraded shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.75 price objective on the stock in a report on Thursday, March 28th. B. Riley assumed coverage on shares of AcelRx Pharmaceuticals in a research note on Wednesday, April 24th. They set a “buy” rating and a $6.50 price target on the stock. ValuEngine upgraded shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, May 1st. Finally, LADENBURG THALM/SH SH reiterated a “buy” rating and set a $10.00 price target on shares of AcelRx Pharmaceuticals in a research note on Thursday, May 9th. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. AcelRx Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $7.47.

Large investors have recently modified their holdings of the business. Weiss Asset Management LP purchased a new stake in shares of AcelRx Pharmaceuticals during the first quarter worth approximately $113,000. Resources Investment Advisors Inc. purchased a new stake in shares of AcelRx Pharmaceuticals during the first quarter worth approximately $34,000. Ahrens Investment Partners LLC purchased a new stake in shares of AcelRx Pharmaceuticals during the first quarter worth approximately $108,000. Mercer Global Advisors Inc. ADV purchased a new stake in shares of AcelRx Pharmaceuticals during the first quarter worth approximately $140,000. Finally, Tibra Equities Europe Ltd purchased a new stake in shares of AcelRx Pharmaceuticals during the first quarter worth approximately $521,000. Institutional investors own 15.53% of the company’s stock.

ACRX traded down $0.08 on Thursday, hitting $2.10. The company had a trading volume of 949,200 shares, compared to its average volume of 1,852,383. The stock has a market cap of $169.66 million, a price-to-earnings ratio of -2.59 and a beta of 2.41. AcelRx Pharmaceuticals has a 1 year low of $1.99 and a 1 year high of $5.05. The stock’s fifty day simple moving average is $2.64. The company has a debt-to-equity ratio of 0.79, a quick ratio of 4.91 and a current ratio of 5.03.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

Featured Story: What is Forex?

Get a free copy of the Zacks research report on AcelRx Pharmaceuticals (ACRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.